Search

Displaying results 631 - 640 of 7555 in total
  1. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722]. … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent

  2. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]

  3. Drug

    Ethchlorvynol

    go.drugbank.com/drugs/DB00189
    ApprovedIllicitWithdrawn

    It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

  4. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    [L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]

  5. Drug

    Technetium Tc-99m disofenin

    go.drugbank.com/drugs/DB09164
    ApprovedWithdrawn

    Technetium Tc-99m is a metastable nuclear isomer and disofenin is an iminodiacetic acid derivative with no known pharmacologic actions at the doses recommended. … However disofenin is the most commonly used iminodiacetic acid since it has a high liver to renal extraction and its hepatic uptake is not as highly dependent on serum bilirubin levels (a competitive inhibitor

  6. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.

  7. Drug

    Buclizine

    go.drugbank.com/drugs/DB00354
    Approved

    It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.

  8. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. … Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate.

  9. Drug

    Acetylsalicylic acid

    go.drugbank.com/drugs/DB00945
    ApprovedInvestigationalVet approved

    Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes.

    Synonyms: o-acetoxybenzoic acid, O-acetylsalicylic acidInternational brands: Nu-seals
  10. Drug

    Niacin

    go.drugbank.com/drugs/DB00627
    ApprovedInvestigationalNutraceutical

    Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

    Mixtures: Super Daily No 2, Ni-C-E-LE PlusCategories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia